Reduction in Medical Technology

Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis

DALLAS, July 7 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today new preclinical data demonstrating that thiarabine shows remarkable efficacy in the prevention and treatment of rheumatoid arthritis (RA). In a well-established animal model...

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

S. MAMEDE DO CORONADO, Portugal, June 29 /PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and sustained decrease in seizure frequency over the long-ter...

New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure

PARSIPPANY, N.J., May 8 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that new data presented at the American Society of Hypertension, Inc. (ASH) Annual Scientific Meeting and Exposition (ASH 2009) in San Francisco from the BeniSILVER study found that BENICAR (R) and BENICAR HCT (R) pro...

Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- The recent announcement of the REDUCE trial results at the American Urological Association annual meeting in Chicago brings optimism to the prostate cancer community as dutasteride (Avodart), a drug used to treat benign prostatic hyperplasia, has...

CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study

NEW ORLEANS, Nov. 9 /PRNewswire-FirstCall/ -- New data from the JUPITER study demonstrated that CRESTOR(R) (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularizatio...

Radioactive Seed Therapy Shows Significant Reduction in Lung Cancer Recurrence

Study Shows near 80% Improvement In Outcomes PITTSBURGH, Sept. 23 /PRNewswire/ -- Radiation oncologists at Allegheny General Hospital (AGH) in Pittsburgh today will report to the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston that a newer, minimally inv...

Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig

WAYNE, Penn., Sept. 22 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO ), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that at ...

New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times

First Patients Treated Using Next Generation CyberKnife System at Oklahoma CyberKnife Center SUNNYVALE, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today that the first patients...

Study Shows Use of AdvanDx's PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream Infections

WOBURN, Mass., July 15 /PRNewswire/ -- AdvanDx today announced that a new study shows use of AdvanDx's PNA FISH(TM) test was associated with an 82% reduction in mortality rates from S. aureus bloodstream infections in the intensive care unit (ICU), a 53% reduction in overall mortality from sta...

Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment

REHOVOT, Israel, July 1 /PRNewswire-FirstCall/ -- Applisonix LTD (TASE: APLS), a developer of innovative ultrasound based solutions for the aesthetic market, announced today that the test conducted using its hair removal prototype achieved, following an initial treatment, average hair reductio...

Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing

- Once-daily dosing with enteric-coated tablet produced robust antiviral activity - - RDEA806 was well tolerated during one week of dosing in HIV patients - SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced add...

Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation

BRIDGEWATER, N.J., May 15 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that findings from the landmark ATHENA study showed Multaq(R) (dronedarone), a potential therapy for the treatment of patients with atrial fibrillation or atrial flutter, decreased ...

Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions

Patch Formulation May Provide New Option for Clinicians Concerned About Systemic Exposure When Using an Oral NSAID TAMPA, Fla., May 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ), a leading global specialty pharmaceutical company, announced today that two studies to be p...

Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis

CARLSBAD, Calif., April 18 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) presented the results of two studies designed to assess the impact of lowering apoB-100 on atherosclerosis at the 2008 Annual Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Conference in A...

RICE MEMORIAL HOSPITAL PHARMACY STAFF EXPERIENCES A 55% REDUCTION IN TIME SPENT MANAGING PATIENT-SPECIFIC MEDICATIONS USING OMNICELL SINGLEPOINTE SOLUTION

Findings of pre- and post study at Rice Memorial Hospital translates into increased efficiency of pharmacist and nursing staff MOUNTAIN VIEW, Calif. and WILLMAR, Minn., April 17 /PRNewswire-FirstCall/ -- Omnicell, Inc. (Nasdaq: OMCL ) a leading provider of system solutions targeting p...

UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting

YOQNEAM, Israel and SAN RAMON, California, April 3 /PRNewswire/ -- Results of an independent multi-treatment clinical study of the UltraShape(R) Contour I, the first clinically proven non-invasive solution for fat reduction and body contouring using non-thermal selective focused ultrasound wil...

Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load

- Company on Track to Initiate Phase 2b in Second Quarter of 2008 - - Conference Call Tomorrow at 8:00 a.m. Eastern Time - SAN DIEGO, March 17 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced positive preliminary results from its ongoing Phase 2a pro...

American Laser Center Offers VelaShape Body Shaping and Cellulite Reduction Treatment

FARMINGTON HILLS, Mich., March 7 /PRNewswire/ -- American Laser Centers, the largest provider of laser hair removal and other noninvasive aesthetic services in the U.S., announces the addition of the VelaShape cellulite reduction and body shaping therapy service in 50 U.S. clinics now and 30 a...

Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System

- Dr. Benjamin Ascher, a Leading French Plastic Surgeon, Will Present his UltraShape Clinical Results at the International Society of Aesthetic Plastic Surgery Meeting in Melbourne, AU From Feb. 10-13 YOQNEAM, Israel and SAN RAMON, Calif., Feb. 10 /PRNewswire/ -- Renowned French Plast...

FreshFx Recognized for use in the Scalder as a Solution to the 'Yield/Pathogen Reduction Dilemma'

Article in Watt Poultry USA states that acidic treatments benefit poultry processing plants. SHREVEPORT, La., Nov. 6 /PRNewswire/ -- FreshFx Antimicrobial Solution, which is used to reduce pathogens during poultry processing, was identified in an October 2007 Watt Poul...

Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome

- Data Presented at the 132nd Annual Meeting of the American Neurological Association in Washington, D.C. - ATLANTA, Oct. 8 /PRNewswire/ -- UCB, Inc. presented results from two Phase III pivotal trials and one open-label extension trial of rotigotine transdermal system for the...

PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials

Analysis published in the journal Blood found 92 percent reduction in incidence of thromboses CHESHIRE, Conn., Aug. 20 /PRNewswire-FirstCall/ -- Patients with a rare blood disorder called PNH experienced a 92 percent reduction in the incidence of life-threatening blood ...

Tekturna, First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan

* New study results show more patients receiving both Tekturna and Diovan reached target blood pressure goal compared to those taking either agent alone EAST HANOVER, N.J., March 26, 2007 /PRNewswire/ -- Results from a new study have shown patients taking two Novartis cardiovascular medicines -- t...

First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan

Unprecedented Evidence for the Effectiveness of Hypertension Treatment Valsartan in Preventing Cardiovascular Events in Japanese Patients TOKYO, April 26, 2007 /Xinhua-PRNewswire/ -- The clinical outcomes of the JIKEI HEART Study, the large-scale clinical trial headed by the Jikei University Schoo...

Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study

Independent Japanese study demonstrates dramatic benefits of adding Diovan to conventional therapy Study halted early due to superior outcomes for Diovan patients BASEL, Switzerland, April 27, 2007 - New findings from the independent Jikei Heart Study, published today in The Lanc...

Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study

Independent Japanese study demonstrates ...

Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)

JERUSALEM, & LUND, Sweden--(BUSINESS WIRE)--May 1, 2007 - Teva Pharmaceutical Industries Ltd. and Active Biotech AB today announced that data from a 36-week, randomized, double-blind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantl...

Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy

Positive interim results prompt request for meeting with FDA SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced today that interim results of its phase II/III trial comparing CPOP-R, in which pixantrone is substituted for doxorubicin in standard CHOP-R first-l...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...that the study met its primary endpoint with a 25% reduction in LDL-C after 26 weeks of treatment with mipomers...H. The study met its primary endpoint, with a 25% reduction in LDL-C after 26 weeks of treatment, vs. 3% for p... also met each of its three secondary endpoints of reduction in apoB, total cholesterol and non-HDL-C. ...

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

..., MD, Chief Medical Officer of Radius. "The greater and faster accrual of BMD with BA058 may allow for shorter durations of treatment and a more rapid reduction in fracture risk in the severe osteoporotic postmenopausal population, which would be a significant advance in the treatment of this debilitating dise...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

...ount, and spleen volume were also demonstrated. The magnitude of changes in the 45U/kg dose was also clinically important, and a trend in liver volume reduction was observed. The 60U/kg dose performed numerically as well or better than 45U/kg across all measured clinical endpoints. The specific data fro...

New Powder Speeds Healing of Difficult Foot Wounds

...ed that they have experienced a foot sore that would not heal. This powder's successful treatment of difficult foot wounds could potentially lead to a reduction in amputation rates. "This new powder aggregates, or comes together, in an amazing flexible film that mimics the wound's surface and helps it t...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

...elated adverse events noted in TASKi3 were diarrhea and hypertension. Dose reduction options were pre-specified in the trial protocol and, in cases where doses ...-- --- --- --- --- # Had a Dose reduction 2 3% 21 14% ----------------------...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

...one strength. Patients who are at increased risk of decreased bone mass should be monitored. Inhaled steroids, including ASMANEX, may cause a reduction in growth velocity when administered to pediatric patients. The long-term effect on final adult height is unknown. Health care providers should closel...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

...ort: End of Treatment Mean Patients with 1 log10 or Change in HCV RNA Greater reduction in HCV Cohort Dose (log10) RNA at End of Treatment ------ ---- --------------------- --------------------...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

...e once weekly experienced a statistically superior reduction in A1C, a measure of average blood sugar over thre...1.5 percentage points from baseline, compared to a reduction of 1.3 percentage points for Lantus after completi...d with exenatide once weekly experienced a greater reduction in blood glucose than those treated with Lantus, t...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

...eceiving BENLYSTA achieved a clinically meaningful reduction in steroid dose. We hope to have a full presentat...ients receiving belimumab achieved a reduction in SELENA SLEDAI score of at least 4...ent response rate at Week 52, as defined by: (1) a reduction from baseline of at least 4 points on the SELENA S...

Elbit Imaging Ltd. Announces - Swiss Team Uses InSightec's ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders

... underwent non-invasive deep brain ablation surgery (central lateral thalamotomy) with transcranial TcMRgFUS and showed improvement in pain scores and reduction of pain medication with no adverse effects at three months follow-up. This is the first study in the world to test non-invasive transcranial focused u...

Results From Trials of DHA in Alzheimer's Disease and Age-Related Cognitive Decline

...ame as for the placebo. "In our study, healthy people with memory complaints who took algal DHA capsules for six months had almost double the reduction in errors on a test that measures learning and memory performance versus those who took a placebo," Yurko-Mauro said. "The benefit is roughly equivale...

ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients

...ct bone strength. Patients who are at increased risk of decreased bone mass should be monitored. Inhaled steroids, including ASMANEX, may cause a reduction in growth velocity when administered to pediatric patients. The long-term effect on final adult height is unknown. Health care providers should closel...